Breaking News

3P Biopharmaceuticals Receives FDA approval

FDA classified 3P facilities as acceptable for manufacture of target molecule, and appropriate for commercialization in the US once product is authorized

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

3P Biopharmaceuticals, a contract development and manufacturing organization (CDMO) specialized in process development and GMP manufacturing of biologics, has received FDA approval after completing the Pre-Approval Inspection (PAI) conducted at the 3P drug substance manufacturing facility. This approval comes after completing the inspection conducted at 3P facilities during January 2019. “To achieve the final approval of the FDA is a great success for a company based in Spain, positioning us at...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters